» Articles » PMID: 34066697

Pneumococcal and Influenza Vaccination Rates and Pneumococcal Invasive Disease Rates Set Geographical and Ethnic Population Susceptibility to Serious COVID-19 Cases and Deaths

Overview
Date 2021 Jun 2
PMID 34066697
Citations 12
Authors
Affiliations
Soon will be listed here.
Abstract

This study examines the relationship of pneumococcal vaccination rates, influenza, measles-mumps-rubella (MMR) diphtheria-tetanus-pertussis vaccinations (DTP), polio, Haemophilus influenzae type B (Hib), and Bacillus Calmette-Guerin (tuberculosis) vaccination rates to COVID-19 case and death rates for 51 nations that have high rates of COVID-19 testing and for which nearly complete childhood, at-risk adult and elderly pneumococcal vaccination data were available. The study is unique in a large number of nations examined, the range of vaccine controls, in testing effects of combinations of vaccinations, and in examining the relationship of COVID-19 and vaccination rates to invasive pneumococcal disease (IPD). Analysis of Italian regions and the states of the United States were also performed. Significant positive correlations were found between IPD (but not lower respiratory infections) and COVID-19 rates, while significant negative correlations were found between pneumococcal vaccination and COVID-19 rates. Influenza and MMR vaccination rates were negatively correlated with lower respiratory infection (LRI) rates and may synergize with pneumococcal vaccination rates to protect against COVID-19. Pneumococcal and influenza vaccination rates were independent of other vaccination rates. These results suggest that endemic rates of bacterial pneumonias, for which pneumococci are a sentinel, may set regional and national susceptibility to severe COVID-19 disease and death.

Citing Articles

Expert panel opinion on adult pneumococcal vaccination in the post-COVID era (NAP- EXPO Recommendations-2024).

Koul P, Vora A, Jindal S, Ramasubramanian V, Narayanan V, Tripathi S Lung India. 2024; 41(4):307-317.

PMID: 38953196 PMC: 11302778. DOI: 10.4103/lungindia.lungindia_8_24.


SARS-CoV-2 and Its Bacterial Co- or Super-Infections Synergize to Trigger COVID-19 Autoimmune Cardiopathies.

Root-Bernstein R, Huber J, Ziehl A, Pietrowicz M Int J Mol Sci. 2023; 24(15).

PMID: 37569555 PMC: 10418384. DOI: 10.3390/ijms241512177.


The Effect of Pneumococcal, Influenza, and COVID-19 Vaccinations on COVID-19 Hospitalization and Progression in People over 65 Years Old Living in Nursing Homes.

Yilmaz F, Cakir M, Ikiisik H, Maral I Vaccines (Basel). 2023; 11(5).

PMID: 37243046 PMC: 10222139. DOI: 10.3390/vaccines11050943.


From Co-Infections to Autoimmune Disease via Hyperactivated Innate Immunity: COVID-19 Autoimmune Coagulopathies, Autoimmune Myocarditis and Multisystem Inflammatory Syndrome in Children.

Root-Bernstein R Int J Mol Sci. 2023; 24(3).

PMID: 36769320 PMC: 9917907. DOI: 10.3390/ijms24033001.


T Cell Receptor Sequences Amplified during Severe COVID-19 and Multisystem Inflammatory Syndrome in Children Mimic SARS-CoV-2, Its Bacterial Co-Infections and Host Autoantigens.

Root-Bernstein R, Churchill E, Oliverio S Int J Mol Sci. 2023; 24(2).

PMID: 36674851 PMC: 9861234. DOI: 10.3390/ijms24021335.


References
1.
Martinelli D, Tafuri S, Caputi G, Fortunato F, Reggio P, Germinario C . Eight years of active proposal of pneumococcal 23-valent polysaccharide vaccine: survey on coverage rate among elderly and chronic patients. Am J Infect Control. 2010; 38(4):e8-e15. DOI: 10.1016/j.ajic.2009.09.019. View

2.
Nguyen M, Lindegaard H, Hendricks O, Friis-Moller N . Factors associated with influenza and pneumococcal vaccine uptake among rheumatoid arthritis patients in Denmark invited to participate in a pneumococcal vaccine trial (Immunovax_RA). Scand J Rheumatol. 2017; 46(6):446-453. DOI: 10.1080/03009742.2016.1242774. View

3.
Allam M, Amin G . BCG Vaccine does not Protect Against COVID-19. Open Respir Med J. 2020; 14:45-46. PMC: 7705950. DOI: 10.2174/1874306402014010045. View

4.
Moorlag S, van Deuren R, van Werkhoven C, Jaeger M, Debisarun P, Taks E . Safety and COVID-19 Symptoms in Individuals Recently Vaccinated with BCG: a Retrospective Cohort Study. Cell Rep Med. 2020; 1(5):100073. PMC: 7405881. DOI: 10.1016/j.xcrm.2020.100073. View

5.
Vajer P, Tamas F, Urban R, Torzsa P, Kalabay L . [Pneumococcal vaccination in general practice]. Orv Hetil. 2015; 156(5):186-91. DOI: 10.1556/OH.2015.30054. View